ClinicalTrials.gg
CompletedNCT03181126Updated Oct 14, 2021

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

A Phase 1 interventional study of Navitoclax and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma, sponsored by AbbVie. Completed at 15 sites in 2 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing venetoclax in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 15 open to participants now, 20 under way, 3 of them phase 3. venetoclax · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
7th of 26
69 · median 38
Started
2017
with 1 other
Phase 1
4 of 26
1 open now
Registered
1st of 26
by date
Lead sponsor
3 of 26
AbbVie

Among the 26 studies testing venetoclax in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 1, and was the 1st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

15 of the 26 studies testing venetoclax in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing venetoclax in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or relapsed/refractory lymphoblastic lymphoma. A safety expansion cohort of approximately 20 patients may be enrolled in addition to the 50 participants in dose-escalation cohort.

03

Conditions studied

  • Acute Lymphoblastic Leukemia (ALL)
  • Lymphoblastic Lymphoma

Keywords

  • Relapsed of Refractory Acute Lymphoblastic Leukemia
  • Cancer
  • Venetoclax
  • Navitoclax
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have acute lymphoblastic leukemia (ALL) or relapsed or refractory lymphoblastic lymphoma (LL). Refractory is defined as persistent disease after at least 2 courses of chemotherapy.

    • Participants with ALL with Philadelphia chromosome or with an ABL class targetable fusion are eligible.
    • Participants with LL must have radiographic evidence of disease
  • Participants \<= 18 years of age who do not have a standard of care treatment option available.
  • Must weigh greater than or equal to 20 kg.
  • Must be able to swallow pills.
  • Must have adequate hepatic and kidney function.
  • Must have adequate performance status:

    • Participants less than or equal to 16 years of age: Lansky greater than or equal to 50
    • Participants greater than 16 years of age: greater than or equal to 50 or (ECOG) less than 3.

Exclusion criteria

Exclusion Criteria:

  • Participant has central nervous system (CNS) disease with cranial involvement that requires radiation.
  • Participants who are less than 100 days post-transplant, or greater than 100 days post-transplant with active (GVHD), or are still continuing post-transplant therapy within 7 days prior to the first dose of study drug.
  • Participants who have received any of the following prior to the first dose of study drug:

    • Inotuzumab within 30 days (if participant received inotuzumab > 30 days prior to Day 1, must have , AST and \< ).
    • A biologic agent (i.e., monoclonal antibodies) for anti-neoplastic intent within 30 days
    • CAR-T infusion or other cellular therapy within 30 days
    • Any anti-cancer therapy including blinatumomab, chemotherapy, radiation therapy targeted small molecule agents or agents within 14 days, or 5 half-lives, whichever is shorter

      • Exception: Philadelphia Chromosome (Ph)+ ALL subjects on TKIs at Screening may enroll and remain on Tyrosine Kinase Inhibitor (TKI) therapy to control disease. Participants on venetoclax at screening may enroll and remain on venetoclax.
    • therapy for anti-neoplastic intent within 5 days
    • Hydroxyurea that is ongoing (hydroxyurea is permitted up to the first dose)
    • A strong or moderate inhibitor or inducer within 7 days
    • Aspirin within 7 days, or 5 half-lives, whichever is longer
    • An excluded antiplatelet/anticoagulant drug or a herbal supplement that affects function within 7 days, or 5 half-lives, whichever is longer
  • Participants with malabsorption syndrome or any other condition that precludes enteral administration.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Venetoclax + Navitoclax + Chemotherapy

    Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase \[or any other forms of asparaginase\], vincristine, dexamethasone) and tyrosine kinase inhibitor \[TKI, if applicable\]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.

    Drug: Navitoclax · Drug: Chemotherapy · Drug: Venetoclax

Interventions

  • tablet

    Also known as: ABT-263

  • DrugChemotherapy

    peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)

  • tablet

    Also known as: ABT-199 GDC-0199

06

What researchers measure

Primary outcomes

  1. Cmax of Venetoclax + Navitoclax

    Maximum observed plasma concentration (Cmax) of venetoclax + navitoclax

    Time frame: Up to approximately 9 months

  2. AUC of Venetoclax + Navitoclax

    Area under the plasma concentration-time curve (AUC) of venetoclax + navitoclax

    Time frame: Up to approximately 9 months

  3. Tmax of Venetoclax + Navitoclax

    Time to Cmax (Tmax) of Venetoclax + Navitoclax

    Time frame: Up to approximately 9 months

  4. CL/F of Venetoclax + Navitoclax

    Apparent oral clearance (CL/F) of venetoclax + navitoclax

    Time frame: Up to approximately 9 months

  5. Number of participants with dose-limiting toxicities (DLT)

    A DLT is any Grade 3 or higher non-hematologic adverse event (AE) with exceptions outlined in the protocol. AEs and toxicities that occur beyond the DLT assessment period will also be evaluated by the investigator and AbbVie and may be considered as dose-limiting.

    Time frame: Up to approximately 28 days after initial dose of study drug

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the number of days from the date of enrollment to the date of earliest disease progression or death.

    Time frame: Up to 9 months after the last subject has enrolled into the study

  2. Partial Response (PR) rate

    PR defined as no peripheral blasts or peripheral blood absolute blast count decreased by ≥ 50% from baseline, bone marrow with 5 - 25% blasts and at least a 50% decrease in bone marrow blast percent from baseline, no evidence of extramedullary disease.

    Time frame: Up to 9 months after the last subject has enrolled into the study

  3. Number of Participant who Proceed to Stem Cell Transplantation or Chimeric antigen receptor T-cell (CAR-T) Therapy

    Determine the number of participants who proceed to stem cell transplantation or CAR-T therapy.

    Time frame: Up to 9 months after the last subject has enrolled into the study

  4. Overall survival (OS)

    OS is defined as the number of days from the date of enrollment to the date of death.

    Time frame: Up to 9 months after the last subject has enrolled into the study

  5. Objective response rate (ORR)

    The proportion of subjects with objective response rate (complete response \[CR\] + CR incomplete recovery \[CRi\] + CR without platelet recovery \[CRp\]) for ALL subjects and (CR+PR) for LL subjects.

    Time frame: Up to 9 months after the last subject has enrolled into the study

  6. Complete Response (CR) rate

    CR defined as hematologic recovery (absolute neutrophil count \[ANC\] greater than or equal to 500/μL; platelet counts greater than or equal to 75,000/μL), evidence of trilineage hematopoiesis in the bone marrow and less than 5% blasts in the bone marrow, absence of circulating blasts, and no evidence of extramedullary disease.

    Time frame: Up to 9 months after the last subject has enrolled into the study

07

Study locations

15 sites
  • City of Hope /ID# 169029
    Duarte, California 91010, United States
  • LPCH Stanford /ID# 163337
    Palo Alto, California 94304, United States
  • University of Chicago /ID# 163369
    Chicago, Illinois 60637, United States
  • Washington University-School of Medicine /ID# 165689
    Saint Louis, Missouri 63110, United States
  • Univ NC Chapel Hill /ID# 163509
    Chapel Hill, North Carolina 27514-4220, United States
  • Cincinnati Children's Hospital /ID# 164619
    Cincinnati, Ohio 45229, United States
  • Nationwide Childrens Hospital /ID# 163372
    Columbus, Ohio 43205, United States
  • Oregon Health and Science University /ID# 165690
    Portland, Oregon 97239, United States
  • St Jude Children's Research Hospital /ID# 163335
    Memphis, Tennessee 38105, United States
  • UT Southwestern Medical Center /ID# 163346
    Dallas, Texas 75390-7208, United States
  • MD Anderson Cancer Center at Texas Medical Center /ID# 163327
    Houston, Texas 77030-4000, United States
  • University of Wisconsin-Madiso /ID# 165691
    Madison, Wisconsin 53705, United States
  • Alfred Hospital /ID# 169576
    Melbourne, Victoria 3004, Australia
  • Victorian Comprehensive Cancer /ID# 165710
    Melbourne, Victoria 3050, Australia
  • Royal Children's Hospital /ID# 163322
    Melbourne, Victoria 3052, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2020, 35 months.

Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's 35 months is below that.

Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 8, 2017
StartActual
Nov 27, 2017
Primary completionActual
Nov 11, 2020
CompletionActual
Nov 14, 2020
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03181126
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Nov 27, 2017
Primary completion
Nov 11, 2020
Completion
Nov 14, 2020
Last update
Oct 14, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Navitoclax · Venetoclax

Start the discussion